Report cover image

Global Ankylosing Spondylitis Treatment Drug Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 203 Pages
SKU # APRC20361732

Description

Summary

According to APO Research, The global Ankylosing Spondylitis Treatment Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ankylosing Spondylitis Treatment Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Ankylosing Spondylitis Treatment Drug include UCB, Abbott, Takeda, Eisai, Guojian Pharmaceutical, Celgen Pharm, Johson & Johson, Novartis and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Ankylosing Spondylitis Treatment Drug, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ankylosing Spondylitis Treatment Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Ankylosing Spondylitis Treatment Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ankylosing Spondylitis Treatment Drug revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ankylosing Spondylitis Treatment Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Ankylosing Spondylitis Treatment Drug revenue, projected growth trends, production technology, application and end-user industry.

Ankylosing Spondylitis Treatment Drug Segment by Company

UCB
Abbott
Takeda
Eisai
Guojian Pharmaceutical
Celgen Pharm
Johson & Johson
Novartis
Merck
Maibo Pharma
Pfizer
Hisun Pharm
Bio-Thera Solutions
Amgen
Abbive
Mitsubishi Tanabe
Ankylosing Spondylitis Treatment Drug Segment by Type

Non-steroidal Anti-inflammatory Drugs
Inhibitor
Ankylosing Spondylitis Treatment Drug Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Other
Ankylosing Spondylitis Treatment Drug Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ankylosing Spondylitis Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ankylosing Spondylitis Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ankylosing Spondylitis Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Ankylosing Spondylitis Treatment Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Ankylosing Spondylitis Treatment Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Ankylosing Spondylitis Treatment Drug revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

203 Pages
1 Market Overview
1.1 Product Definition
1.2 Ankylosing Spondylitis Treatment Drug Market by Type
1.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Non-steroidal Anti-inflammatory Drugs
1.2.3 Inhibitor
1.3 Ankylosing Spondylitis Treatment Drug Market by Application
1.3.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Retail Pharmacy
1.3.3 Online Pharmacy
1.3.4 Hospital Pharmacy
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Ankylosing Spondylitis Treatment Drug Market Dynamics
2.1 Ankylosing Spondylitis Treatment Drug Industry Trends
2.2 Ankylosing Spondylitis Treatment Drug Industry Drivers
2.3 Ankylosing Spondylitis Treatment Drug Industry Opportunities and Challenges
2.4 Ankylosing Spondylitis Treatment Drug Industry Restraints
3 Global Growth Perspective
3.1 Global Ankylosing Spondylitis Treatment Drug Market Perspective (2020-2031)
3.2 Global Ankylosing Spondylitis Treatment Drug Growth Trends by Region
3.2.1 Global Ankylosing Spondylitis Treatment Drug Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2020-2025)
3.2.3 Global Ankylosing Spondylitis Treatment Drug Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Players
4.1.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Players (2020-2025)
4.1.2 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Players (2020-2025)
4.1.3 Global Ankylosing Spondylitis Treatment Drug Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Ankylosing Spondylitis Treatment Drug Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Ankylosing Spondylitis Treatment Drug Key Players Headquarters & Area Served
4.4 Global Ankylosing Spondylitis Treatment Drug Players, Product Type & Application
4.5 Global Ankylosing Spondylitis Treatment Drug Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Ankylosing Spondylitis Treatment Drug Market CR5 and HHI
4.6.3 2024 Ankylosing Spondylitis Treatment Drug Tier 1, Tier 2, and Tier 3
5 Ankylosing Spondylitis Treatment Drug Market Size by Type
5.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
5.3 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Type (2020-2031)
6 Ankylosing Spondylitis Treatment Drug Market Size by Application
6.1 Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
6.3 Global Ankylosing Spondylitis Treatment Drug Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 UCB
7.1.1 UCB Comapny Information
7.1.2 UCB Business Overview
7.1.3 UCB Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.1.4 UCB Ankylosing Spondylitis Treatment Drug Product Portfolio
7.1.5 UCB Recent Developments
7.2 Abbott
7.2.1 Abbott Comapny Information
7.2.2 Abbott Business Overview
7.2.3 Abbott Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.2.4 Abbott Ankylosing Spondylitis Treatment Drug Product Portfolio
7.2.5 Abbott Recent Developments
7.3 Takeda
7.3.1 Takeda Comapny Information
7.3.2 Takeda Business Overview
7.3.3 Takeda Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.3.4 Takeda Ankylosing Spondylitis Treatment Drug Product Portfolio
7.3.5 Takeda Recent Developments
7.4 Eisai
7.4.1 Eisai Comapny Information
7.4.2 Eisai Business Overview
7.4.3 Eisai Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.4.4 Eisai Ankylosing Spondylitis Treatment Drug Product Portfolio
7.4.5 Eisai Recent Developments
7.5 Guojian Pharmaceutical
7.5.1 Guojian Pharmaceutical Comapny Information
7.5.2 Guojian Pharmaceutical Business Overview
7.5.3 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.5.4 Guojian Pharmaceutical Ankylosing Spondylitis Treatment Drug Product Portfolio
7.5.5 Guojian Pharmaceutical Recent Developments
7.6 Celgen Pharm
7.6.1 Celgen Pharm Comapny Information
7.6.2 Celgen Pharm Business Overview
7.6.3 Celgen Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.6.4 Celgen Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
7.6.5 Celgen Pharm Recent Developments
7.7 Johson & Johson
7.7.1 Johson & Johson Comapny Information
7.7.2 Johson & Johson Business Overview
7.7.3 Johson & Johson Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.7.4 Johson & Johson Ankylosing Spondylitis Treatment Drug Product Portfolio
7.7.5 Johson & Johson Recent Developments
7.8 Novartis
7.8.1 Novartis Comapny Information
7.8.2 Novartis Business Overview
7.8.3 Novartis Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.8.4 Novartis Ankylosing Spondylitis Treatment Drug Product Portfolio
7.8.5 Novartis Recent Developments
7.9 Merck
7.9.1 Merck Comapny Information
7.9.2 Merck Business Overview
7.9.3 Merck Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.9.4 Merck Ankylosing Spondylitis Treatment Drug Product Portfolio
7.9.5 Merck Recent Developments
7.10 Maibo Pharma
7.10.1 Maibo Pharma Comapny Information
7.10.2 Maibo Pharma Business Overview
7.10.3 Maibo Pharma Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.10.4 Maibo Pharma Ankylosing Spondylitis Treatment Drug Product Portfolio
7.10.5 Maibo Pharma Recent Developments
7.11 Pfizer
7.11.1 Pfizer Comapny Information
7.11.2 Pfizer Business Overview
7.11.3 Pfizer Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.11.4 Pfizer Ankylosing Spondylitis Treatment Drug Product Portfolio
7.11.5 Pfizer Recent Developments
7.12 Hisun Pharm
7.12.1 Hisun Pharm Comapny Information
7.12.2 Hisun Pharm Business Overview
7.12.3 Hisun Pharm Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.12.4 Hisun Pharm Ankylosing Spondylitis Treatment Drug Product Portfolio
7.12.5 Hisun Pharm Recent Developments
7.13 Bio-Thera Solutions
7.13.1 Bio-Thera Solutions Comapny Information
7.13.2 Bio-Thera Solutions Business Overview
7.13.3 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.13.4 Bio-Thera Solutions Ankylosing Spondylitis Treatment Drug Product Portfolio
7.13.5 Bio-Thera Solutions Recent Developments
7.14 Amgen
7.14.1 Amgen Comapny Information
7.14.2 Amgen Business Overview
7.14.3 Amgen Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.14.4 Amgen Ankylosing Spondylitis Treatment Drug Product Portfolio
7.14.5 Amgen Recent Developments
7.15 Abbive
7.15.1 Abbive Comapny Information
7.15.2 Abbive Business Overview
7.15.3 Abbive Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.15.4 Abbive Ankylosing Spondylitis Treatment Drug Product Portfolio
7.15.5 Abbive Recent Developments
7.16 Mitsubishi Tanabe
7.16.1 Mitsubishi Tanabe Comapny Information
7.16.2 Mitsubishi Tanabe Business Overview
7.16.3 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Revenue and Gross Margin (2020-2025)
7.16.4 Mitsubishi Tanabe Ankylosing Spondylitis Treatment Drug Product Portfolio
7.16.5 Mitsubishi Tanabe Recent Developments
8 North America
8.1 North America Ankylosing Spondylitis Treatment Drug Revenue (2020-2031)
8.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
8.2.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2025)
8.2.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Type (2026-2031)
8.3 North America Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2020-2031)
8.4 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
8.4.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2025)
8.4.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Application (2026-2031)
8.5 North America Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2020-2031)
8.6 North America Ankylosing Spondylitis Treatment Drug Revenue by Country
8.6.1 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2020-2025)
8.6.3 North America Ankylosing Spondylitis Treatment Drug Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Ankylosing Spondylitis Treatment Drug Revenue (2020-2031)
9.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
9.2.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2025)
9.2.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Type (2026-2031)
9.3 Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2020-2031)
9.4 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
9.4.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2025)
9.4.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Application (2026-2031)
9.5 Europe Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2020-2031)
9.6 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country
9.6.1 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2020-2025)
9.6.3 Europe Ankylosing Spondylitis Treatment Drug Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Ankylosing Spondylitis Treatment Drug Revenue (2020-2031)
10.2 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
10.2.1 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2025)
10.2.2 China Ankylosing Spondylitis Treatment Drug Revenue by Type (2026-2031)
10.3 China Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2020-2031)
10.4 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
10.4.1 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2025)
10.4.2 China Ankylosing Spondylitis Treatment Drug Revenue by Application (2026-2031)
10.5 China Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Ankylosing Spondylitis Treatment Drug Revenue (2020-2031)
11.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
11.2.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2025)
11.2.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Type (2026-2031)
11.3 Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2020-2031)
11.4 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
11.4.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2025)
11.4.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Application (2026-2031)
11.5 Asia Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2020-2031)
11.6 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country
11.6.1 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2020-2025)
11.6.3 Asia Ankylosing Spondylitis Treatment Drug Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue (2020-2031)
12.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2031)
12.2.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2020-2025)
12.2.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Type (2026-2031)
12.3 SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Type (2020-2031)
12.4 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2031)
12.4.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2020-2025)
12.4.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Application (2026-2031)
12.5 SAMEA Ankylosing Spondylitis Treatment Drug Revenue Share by Application (2020-2031)
12.6 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country
12.6.1 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2020-2025)
12.6.3 SAMEA Ankylosing Spondylitis Treatment Drug Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.